公开(公告)号：JP2003096057A

公开(公告)日：2003-04-03

申请号：JP2002205661

申请日：2002-07-15

Applicant: SERVIER LAB

Inventor： LABIDALLE SERGE ,  TILLEMENT JEAN PAUL ,  TESTA BERNARD ,  CECCHELLI ROMEO ,  LE RIDANT ALAIN ,  HARPEY CATHERINE ,  SPEDDING MICHAEL ,  SCHENKER ESTHER

IPC: C07D295/08 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61P9/00 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P41/00 ,  C07D239/42 ,  C07D239/50 ,  C07D295/03 ,  C07D295/092 ,  C07D295/096 ,  C07D295/14 ,  C07D295/15

Abstract: PROBLEM TO BE SOLVED: To provide a pharmaceutical composition which is useful for prevention or treatment of cellular ischemia, ischemic brain, ischemic heart or peripheral ischemia; treatment of chronic neurodegenerative symptoms, and for storage of organs for the purpose of transplantation, as well as for improving recovery of functioning transplant piece of after being reperfused. SOLUTION: An N-benzylpiperazine compound is represented by formula (I), [wherein, R1 is a straight chain or branched chain (C1 -C6 ) alkyl group; R2 is a hydroxyl group or the like; R3 is a hydrogen atom or the like; n is an integer of 1 to 12], and an optical isomer thereof, an addition salt thereof with a pharmaceutically acceptable acid or base, and a method for preparing thereof, as well as a pharmaceutical composition containing said compound are provided.

公开(公告)号：WO2008071869A2

公开(公告)日：2008-06-19

申请号：PCT/FR2007001925

申请日：2007-11-23

Applicant: SERVIER LAB ,  SPEDDING MICHAEL ,  MOCAER ELISABETH

Inventor： SPEDDING MICHAEL ,  MOCAER ELISABETH

CPC classification number: A61K31/165

Abstract: The invention relates to the use of agomelatine or N-[2-(7-methoxy-1-naphtyl)ethyl]acetamide in order to obtain drugs intended for the treatment of periventricular leukomalacia.

Abstract translation: 本发明涉及阿戈美拉汀或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺以获得用于治疗脑室周围白质软化症的药物的用途。

公开(公告)号：WO2009022066A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000935

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C233/18 ,  A61K31/165 ,  A61P25/00

CPC classification number: C07C233/18

Abstract: Compound of formula (I): Medicaments.

Abstract translation: 式（I）化合物：药物。

公开(公告)号：WO2009022063A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000932

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C251/48 ,  A61K31/165 ,  A61P25/00

CPC classification number: C07C251/48

Abstract: Compounds of formula (I): in which: R1 is an alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and X is an N-OR2 group in which R2 is a hydrogen atom or an alkyl group. Medicaments.

Abstract translation: 式（I）化合物：其中：R 1是烷基，链烯基，卤代烷基，多卤代烷基，环烷基，环烷基烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，X是N-OR 2基团，其中R 2是氢原子或 烷基。 药物。

公开(公告)号：WO2009022065A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000934

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C233/18 ,  A61K31/165 ,  A61P25/00

CPC classification number: C07C233/18

Abstract: Compounds of formula (I): in which: R1 is an alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and R2 and R3 are a hydrogen atom or an alkyl group. Medicaments.

Abstract translation: 式（I）化合物：其中：R1是烷基，烯基，卤代烷基，多卤代烷基，环烷基，环烷基烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，R2和R3是氢原子或烷基。 药物。

公开(公告)号：WO2009022064A3

公开(公告)日：2009-04-16

申请号：PCT/FR2008000933

申请日：2008-07-01

Applicant: SERVIER LAB ,  YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

Inventor： YOUS SAID ,  ETTAOUSSI MOHAMED ,  SABAOUNI AHMED ,  BERTHELOT PASCAL ,  SPEDDING MICHAEL ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI ,  MILLAN MARK

IPC: C07C233/18 ,  A61K31/165 ,  A61P25/00 ,  C07C233/60

CPC classification number: C07C233/18 ,  C07C233/60 ,  C07C2601/02 ,  C07C2601/04

Abstract: Compounds of formula (I): in which: R1 is alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and R2 is a fluorine atom or an alkyl group substituted with one or more fluorine atoms. Medicaments.

Abstract translation: 式（I）的化合物：其中：R1是烷基，烯基，卤代烷基，多卤代烷基，环烷基，环烷基烷基，芳基，芳烷基，杂芳基或杂芳基烷基，R2是氟原子或被一个或多个氟原子取代的烷基。 药物。

公开(公告)号：CU24134B1

公开(公告)日：2015-11-27

申请号：CU20120041

申请日：2012-03-08

Applicant: SERVIER LAB ,  EGIS GYOGYSZERGYAR NYRT

Inventor： LING ISTVÁN ,  BARKÓCZY JÓZSEF ,  ANTONI FERENC ,  GACSÁLYI ISTVÁN ,  LÉVAY GYÖRGY ,  SPEDDING MICHAEL ,  HÁRSING LÁSZLÓ

IPC: C07D243/38

Abstract: La invención se refiere a nuevos compuestos dihidro-oxazolobenzodiazepinone de fórmula (I): ESPACIO PARA LA FÓRMULA en la que: R1 representa un átomo de hidrógeno o un grupo alquilo; R2 representa un grupo alquilo y R3 representa un grupo arilo o heteroarilo; a un procedimiento para su preparación y a composiciones farmacéuticas que los contienen. Los compuestos de la presente invención son selectivos de la subunidad alfa5 del receptor GABAA y disminuyen los efectos del neurotransmisor GABA.

公开(公告)号：AP3344A

公开(公告)日：2015-07-31

申请号：AP2012006149

申请日：2012-03-06

Applicant: SERVIER LAB ,  EGIS GYOGYSZERGYAR NYRT

Inventor： SPEDDING MICHAEL ,  ANTONI FERENC ,  HARSING LASZLO

IPC: A61K31/551 ,  C07D498/04

Abstract: Dihydro-oxazolobenzodiazepinone derivatives (I) are new. Dihydro-oxazolobenzodiazepinone derivatives of formula (I) and their positional isomers, enantiomers, diastereoisomers or addition salts with acids, solvates, complexes or adducts, are new. R1 : H or 1-4C alkyl; R2 : 1-4C alkyl; and R3 : (hetero)aryl. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Neuroleptic; Antidepressant; Neuroprotective; Nootropic; Antiparkinsonian; Anticonvulsant; Tranquilizer; Vulnerary; Cerebroprotective. MECHANISM OF ACTION : gamma -Aminobutyric acid (GABA) receptor agonist. The GABA receptor agonistic activity of (I) was tested in human embryonic kidney (HEK-293) cells. The result showed that 5-(6-fluoro-1-benzothien-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one exhibited an IC 5 0value of 100 nM.

公开(公告)号：PT2497774E

公开(公告)日：2013-11-26

申请号：PT12290077

申请日：2012-03-07

Applicant: SERVIER LAB ,  EGIS GYOGYSZERGYAR NYRT

Inventor： GACSALYI ISTVAN ,  LING ISTVAN ,  SPEDDING MICHAEL ,  LEVAY GYOERGY ,  BARKOCZY JOZSEF ,  ANTONI FERENC ,  HARSING LASZLO

IPC: C07D498/04 ,  A61K31/551

公开(公告)号：CU20120041A7

公开(公告)日：2013-10-29

申请号：CU20120041

申请日：2012-03-08

Applicant: SERVIER LAB ,  EGIS GYOGYSZERGYAR NYRT

Inventor： LING ISTVÁN ,  BARKÓCZY JÓZSEF ,  ANTONI FERENC ,  GACSÁLYI ISTVÁN ,  LÉVAY GYÖRGY ,  SPEDDING MICHAEL ,  HÁRSING LÁSZLÓ

IPC: C07D243/38

Abstract: Compuestos de fórmula (I): en la que: R1 representa un átomo de hidrógeno o un grupo alquilo; R2 representa un grupo alquilo; R3 representa un grupo arilo o heteroarilo.